Aravive, Inc. (ARAV) SEC Filing 10-Q Quarterly report for the period ending Sunday, June 30, 2019

Aravive, Inc.

CIK: 1513818 Ticker: ARAV


Exhibit 99.1



Aravive Reports Second Quarter 2019 Financial Results and Provides Recent Corporate Updates



HOUSTON – August 7, 2019 –

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, announced recent corporate updates and financial results for the quarter ended June 30, 2019.


“We continue to advance AVB-500 on multiple fronts and are very encouraged by the recent safety and topline efficacy data we reported in our AVB-500 clinical program in platinum-resistant recurrent ovarian cancer,” said Jay Shepard, president and CEO of Aravive. “The first half of the year is off to a strong start and we are making progress toward initiating additional clinical programs.”


Recent Corporate Updates




AVB-500 is an ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway. By capturing serum GAS6, AVB-500 starves the AXL pathway of its signal, potentially halting the biological programming that promotes disease progression. AXL receptor signaling plays an important role in multiple types of malignancies by promoting metastasis, cancer cell survival, resistance to treatments, and immune suppression. The GAS6-AXL signaling pathway also plays a significant role in fibrogenesis. Below are some recent highlights from the ovarian cancer program:



On July 8, we reported that data from the first six patients enrolled into two cohorts (n=12) of the Phase 1b portion of the Phase 1b/2 trial of AVB-500 in patients with platinum-resistant recurrent ovarian cancer, one investigating a combination of AVB-500 with pegylated liposomal doxorubicin (PLD), and the other, a combination of AVB-500 with paclitaxel (PAC) was evaluated by an independent data monitoring committee (DMC). The data demonstrated suppression of serum GAS6 levels, a biomarker associated with efficacy in preclinical tumor models, with the current dose. The DMC did not identify safety concerns and unanimously recommended the trial continue as planned.



On July 31, we announced that the preliminary efficacy data from our ongoing clinical trial with AVB-500, as described above, showed compelling anti-tumor activity in the 12 patients treated where response to standard of care chemotherapy alone in patients is typically 10-15 percent. The overall best response rate (ORR) in the AVB-500 combination cohorts to date by investigator determined RECIST v1.1 criteria was greater than response rates observed historically with


The following information was filed by Aravive, Inc. (ARAV) on Wednesday, August 7, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Aravive, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aravive, Inc..


Assess how Aravive, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aravive, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors




Learn More
Bullish Bearish Neutral
Filter by Sentiment:
Filter by Category:
Filter by Subcategory:
Inside Aravive, Inc.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets (Unaudited)
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Condensed Statements Of Stockholders' Equity (Unaudited)
Balance Sheet Components
Balance Sheet Components (Tables)
Balance Sheet Components - Accrued Liabilities (Detail)
Balance Sheet Components - Additional Information (Detail)
Balance Sheet Components - Prepaid Expenses And Other Current Assets (Detail)
Balance Sheet Components - Property And Equipment, Net (Detail)
Commitments And Contingencies
Commitments And Contingencies - Additional Information (Detail)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Financial Instruments Measured At Fair Value On Recurring Basis (Detail)
Formation And Business Of The Company
Formation And Business Of The Company - Additional Information (Detail)
Leases (Tables)
Leases - Additional Information (Detail)
Leases - Schedule Of Future Sublease Income Term (Detail)
Leases - Summary Of Minimum Lease Payments Under Non-Cancelable Operating Leases (Detail)
Net Loss Per Share Of Common Stock
Net Loss Per Share Of Common Stock (Tables)
Net Loss Per Share Of Common Stock - Summary Of Computation Of Basic And Diluted Net Loss Per Share (Detail)
Stock Based Awards - Summary Of Stock Options Activity (Detail)
Stockholder's Equity
Stockholder's Equity (Tables)
Stockholder's Equity - Additional Information (Detail)
Stockholder's Equity - Summary Of Fair Value Of Employee Stock Options (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Summary Of Significant Accounting Policies - Schedule Of Estimated Stock-Based Compensation Expense (Detail)
Ticker: ARAV
CIK: 1513818
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-19-030079
Submitted to the SEC: Wed Aug 07 2019 12:16:33 PM EST
Accepted by the SEC: Wed Aug 07 2019
Period: Sunday, June 30, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: